A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma
FOCUS | LETTERS FOCUShttps://doi.org/10.1038/s41591-019-0357-y | LETTERS https://doi.org/10.1038/s41591-019-0357-y A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma Alexander C. Huang 1,2,3,4,16*, Robert J. Orlowski1,11,16, Xiaowei Xu4,5, Rosemarie Mick3,4,6, Sangeeth M. George7,12, Patrick K. Yan 2,7, Sasikanth Manne2,7, Adam A. Kraya1,4, Bradley Wubbenhorst1,4, Liza Dorfman1,4, Kurt D’Andrea1,4, Brandon M. Wenz1,4, Shujing Liu4,5, Lakshmi Chilukuri2,7, Andrew Kozlov4,8, Mary Carberry1,4, Lydia Giles1,4, Melanie W. Kier1, Felix Quagliarello2,13, Suzanne McGettigan1,4, Kristin Kreider1,4, Lakshmanan Annamalai9, Qing Zhao9, Robin Mogg9,14, Wei Xu1,4, Wendy M. Blumenschein9, Jennifer H. Yearley9, Gerald P. Linette1,2,3,4, Ravi K. Amaravadi1,4, Lynn M. Schuchter1,4, Ramin S. Herati1,2, Bertram Bengsch2,15, Katherine L. Nathanson1,3,4, Michael D. Farwell4,8,17, Giorgos C. Karakousis4,10,17, E. John Wherry 2,3,4,7,17* and Tara C. Mitchell 1,4,17* Immunologic responses to anti-PD-1 therapy in mela- Clinical responses to anti-PD-1 therapies can occur rapidly1,2. A noma patients occur rapidly with pharmacodynamic T cell pharmacodynamic response including reinvigoration of exhausted- responses detectable in blood by 3 weeks. It is unclear, how- phenotype CD8 T cells (TEX) can be detected in blood of cancer ever, whether these early blood-based observations trans- patients after a single dose3,4. However, the precise type(s) of T cells late to the tumor microenvironment.
[Show full text]